DK1804804T3 - 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser - Google Patents

3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser

Info

Publication number
DK1804804T3
DK1804804T3 DK05801120.6T DK05801120T DK1804804T3 DK 1804804 T3 DK1804804 T3 DK 1804804T3 DK 05801120 T DK05801120 T DK 05801120T DK 1804804 T3 DK1804804 T3 DK 1804804T3
Authority
DK
Denmark
Prior art keywords
oxazepin
dibenzo
piperazin
treatment
sleep disorders
Prior art date
Application number
DK05801120.6T
Other languages
Danish (da)
English (en)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Application granted granted Critical
Publication of DK1804804T3 publication Critical patent/DK1804804T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20[b, f]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05801120.6T 2004-09-21 2005-09-21 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser DK1804804T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19
PCT/US2005/034015 WO2006034414A2 (en) 2004-09-21 2005-09-21 Loxapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
DK1804804T3 true DK1804804T3 (da) 2012-02-20

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05801120.6T DK1804804T3 (da) 2004-09-21 2005-09-21 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser

Country Status (19)

Country Link
US (3) US7592333B2 (enExample)
EP (1) EP1804804B1 (enExample)
JP (1) JP5049129B2 (enExample)
KR (1) KR101264444B1 (enExample)
AT (1) ATE542536T1 (enExample)
AU (1) AU2005286713B2 (enExample)
BR (1) BRPI0515518A (enExample)
CA (1) CA2580250C (enExample)
CY (1) CY1112590T1 (enExample)
DK (1) DK1804804T3 (enExample)
EA (1) EA012610B1 (enExample)
ES (1) ES2378452T3 (enExample)
MA (1) MA28985B1 (enExample)
MX (1) MX2007003032A (enExample)
NO (1) NO20071604L (enExample)
NZ (1) NZ553900A (enExample)
PL (1) PL1804804T3 (enExample)
PT (1) PT1804804E (enExample)
WO (1) WO2006034414A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
WO2006049734A2 (en) * 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
RU2459811C2 (ru) * 2006-10-28 2012-08-27 Метилджен Инк. Ингибиторы гистоновой деацетилазы
BRPI0808828A8 (pt) * 2007-03-15 2017-11-28 Aryx Therapeutics Inc Compostos de dibenzo[b,f][1,4]oxazapina
US8827979B2 (en) 2007-03-19 2014-09-09 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
CN102245137A (zh) 2008-11-07 2011-11-16 茵苏莱恩医药有限公司 用于药物递送的装置和方法
WO2014116684A1 (en) * 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
AU2020370063B2 (en) * 2019-10-21 2025-10-23 Alairion, Inc. 3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propanoic acid derivatives as H1 and 5-HT2A-receptor modulators for the treatment of sleep disorders
WO2025076527A1 (en) * 2023-10-07 2025-04-10 Inspire Medical Systems, Inc. Pulmonary therapy for sleep disordered breathing care

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (enExample) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US20050049146A1 (en) 2001-11-05 2005-03-03 Chiarello John F. Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
EP1578198A1 (en) 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
MX2007003032A (es) 2007-05-21
MA28985B1 (fr) 2007-11-01
US7592333B2 (en) 2009-09-22
NZ553900A (en) 2010-10-29
EP1804804B1 (en) 2012-01-25
WO2006034414A2 (en) 2006-03-30
EA200700702A1 (ru) 2007-10-26
PT1804804E (pt) 2012-03-30
US20090186872A1 (en) 2009-07-23
WO2006034414A3 (en) 2006-09-08
CY1112590T1 (el) 2016-02-10
JP5049129B2 (ja) 2012-10-17
NO20071604L (no) 2007-06-20
EA012610B1 (ru) 2009-10-30
PL1804804T3 (pl) 2012-08-31
AU2005286713A1 (en) 2006-03-30
EP1804804A2 (en) 2007-07-11
AU2005286713B2 (en) 2010-10-28
CA2580250A1 (en) 2006-03-30
KR101264444B1 (ko) 2013-05-20
EP1804804A4 (en) 2010-11-24
CA2580250C (en) 2013-05-14
US20060063928A1 (en) 2006-03-23
ES2378452T3 (es) 2012-04-12
US8101596B2 (en) 2012-01-24
US20060063755A1 (en) 2006-03-23
KR20070060126A (ko) 2007-06-12
BRPI0515518A (pt) 2008-07-29
ATE542536T1 (de) 2012-02-15
JP2008513510A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
DK1804804T3 (da) 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602004021585D1 (de) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
ATE439863T1 (de) Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
CY1108703T1 (el) Αλλοστερικοι ρυθμιστες μεταβολοτροπων υποδοχεων γλουταμικου
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
WO2006060314A3 (en) Generation of replication competent viruses for therapeutic use
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
EA201001358A1 (ru) Активаторы глюкокиназы
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
EA200802054A1 (ru) Ингибиторы фермента
ATE297922T1 (de) Isoindolin-1-on als glukokinaseaktivatoren
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE602004014955D1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)-ethylcyclohexanol-derivate als monoamin-wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen